Sponsored by
Interim analysis from the Phase 2/3 CLINGLIO trial suggests that adding the investigational therapy LAM561 to standard treatment may improve progression free survival (PFS) in newly diagnosed glioblastoma patients with MGMT methylation. While LAM561 was generally well tolerated, it didn't significantly improve PFS in the overall study population. However, in GBM patients with MGMT-methylated tumors, the LAM561 group had a median PFS of 86.4 weeks compared to 54.7 weeks for standard of care alone. Final trial results, including the drug's effect on overall survival, are expected by the end of 2026.